Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Equity Analyst Coverage by Fundamental Research Corp. with a “Buy” Recommendation
March 16, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, March 16, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next generation biopharma company, announces initiation of equity analyst coverage by Fundamental Research...
Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Equity Analyst Coverage by EF Hutton with a “Buy” Recommendation
March 14, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, March 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next generation biopharma company, announces initiation of equity analyst coverage by EF Hutton with a...
Ocean Biomedical (NASDAQ: OCEA) Shares Detailed Research Data on Anti-Tumor Pathway Discoveries and Their Potential for Treatment of Non-Small Cell Lung Cancer, Metastatic Melanoma, and Glioblastoma by Scientific Co-founder
March 09, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, March 09, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA). Ocean Biomedical’s Scientific Co-founder, Dr. Jack A. Elias, MD, presented details of his previously...
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Award of New Patent to Scientific Co-Founder Dr. Jake Kurtis for Novel Malaria Vaccine Target
February 28, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Breakthrough approach targets stage in malaria lifecycle responsible for all clinical disease and death, has potentially significantly greater efficacy compared with vaccines targeting other stages ...
Ocean Biomedical (NASDAQ: OCEA) Celebrates Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%
February 23, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- As previously announced, Ocean Biomedical, Inc. (NASDAQ: OCEA) celebrates the discovery of bispecific antibodies that target Chitinase 3-like-1 and...
Ocean Biomedical to Ring The Nasdaq Stock Market Opening Bell
February 16, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Ocean Biomedical commenced trading on Nasdaq under ticker symbol "OCEA" on February 15 Providence, RI and New York, NY, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (“the Company”),...
Ocean Biomedical Debuts as Publicly Traded Company Focused on Accelerating the Commercialization of Innovative Assets from Research Universities and Medical Centers
February 15, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Completes business combination with Aesther Healthcare Acquisition Corp. Ocean Biomedical stock will trade on Nasdaq under ticker symbol "OCEA" Providence, RI and New York, NY, Feb. 15, 2023 ...
Ocean Biomedical and Aesther Healthcare Acquisition Corp. Announce the Award of New Patents for Novel Monospecific and Bispecific Antibodies that Suppress Multiple Cancer Types
February 09, 2023 09:15 ET
|
Aesther Healthcare Acquisition Corp.
Multiple Patents granted for Methods and Composition for Mono-specific and Bi-specific antibody approaches that suppress tumors by targeting and neutralizing elevated levels of chitinase 3-like-1...
Aesther and Ocean Biomedical Announce Shareholder Approval of Business Combination
February 06, 2023 09:15 ET
|
Aesther Healthcare Acquisition Corp.
NEW YORK and PROVIDENCE, R.I, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special purpose acquisition company (“SPAC”) and Ocean Biomedical,...
Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Measures regarding Excise Tax
February 01, 2023 17:43 ET
|
Aesther Healthcare Acquisition Corp.
NEW YORK and PROVIDENCE, R.I., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special purpose acquisition company (SPAC) and Ocean Biomedical,...